Blog
New Year, new pharma operating model: 2026 resolutions for life sciences commercialization
Here’s a rundown, based on inputs from 120 execs, of how leaders plan to address the cohesion deficit across strategy, tech, data, and...
2026 life sciences commercialization priorities: What’s funded, in the cart, and on the wish list
From chatbots to agents: How GPT-5 is reshaping healthcare and pharma
Rethinking Life Sciences Commercialization for 2026: What’s Working, What’s Not and What’s Next
Research premiere for ‘Commercialization that Works’; direct channels reignite pharma’s patient-centricity hopes
How AI can keep life sciences innovation moving despite funding and staffing cuts
How to confront biopharma's crisis of cohesion
The new pharma equation: How DTP, DTC, and DTE are re-wiring healthcare around patients
How to make cell and gene therapy commercialization work with Rita Johnson-Greene
Introducing Beghou Arc™: Redefining life sciences commercialization
How to make cell and gene therapy commercialization work
.png?width=400&height=250&name=Blog%20(6).png)